middle.news
Actinogen Clears Path to XanaMIA Alzheimer’s Trial Readout
10:33am on Tuesday 17th of November, 2026 AEDT
•
Biotechnology
Read Story
Actinogen Clears Path to XanaMIA Alzheimer’s Trial Readout
10:33am on Tuesday 17th of November, 2026 AEDT
Key Points
Immediate ASX suspension pending XanaMIA topline results
Additional clinical trial data received on 17 November
247-patient phase 2b/3 trial testing Xanamem 10 mg
Primary endpoint is the CDR-SB dementia scale
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Actinogen Medical (ASX:ACW)
OPEN ARTICLE